Therefore, the combination of arsenic trioxide and multi-targeted TKIs (sorafenib and quizartinib) has the potential to improve the outcomes of FLT3-ITD AML patients, which may be also effective in non-FLT3-ITD patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.